OTCMKTS:GSTC

GlobeStar Therapeutics (GSTC) Stock Price, News & Analysis

$0.0009
0.00 (0.00%)
(As of 04/26/2024 08:54 PM ET)
Today's Range
$0.0008
$0.0009
50-Day Range
N/A
52-Week Range
$0.0006
$0.0082
Volume
39,900 shs
Average Volume
11.32 million shs
Market Capitalization
$1.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GSTC stock logo

About GlobeStar Therapeutics Stock (OTCMKTS:GSTC)

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in Richland, Washington.

GSTC Stock Price History

GSTC Stock News Headlines

KHTRF Knight Therapeutics Inc.
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
GlobeStar Therapeutics Corp GSTC
Penny Stocks On The Move: HALB, NHMD, IFUS, GSTC
The Gold Grab of the Century
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
GlobeStar Therapeutics Corporation (GSTC)
GlobeStar Therapeutics Corp
GlobeStar Therapeutics Corp (GSTC)
See More Headlines
Receive GSTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlobeStar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/29/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:GSTC
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

Net Income
$-1,950,000.00
Pretax Margin
N/A
Return on Assets
-75,007.21%

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Outstanding Shares
1,162,920,000
Free Float
1,133,848,000
Market Cap
$1.05 million
Optionable
Not Optionable
Beta
1.49
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. James C. Katzaroff (Age 67)
    President, CEO, Secretary, Principal Executive Officer & Chairman of the Board
    Comp: $180k
  • Mr. Robert R. Hale Chicoski CPA (Age 81)
    CFO, Treasurer, Secretary, Principal Financial & Accounting Officer
    Comp: $84k
  • Ms. Brooke Greenwald
    Chief Marketing Officer
  • Mr. David Croom
    Executive Vice President

GSTC Stock Analysis - Frequently Asked Questions

How have GSTC shares performed in 2024?

GlobeStar Therapeutics' stock was trading at $0.0009 at the beginning of the year. Since then, GSTC stock has increased by 0.0% and is now trading at $0.0009.
View the best growth stocks for 2024 here
.

Are investors shorting GlobeStar Therapeutics?

GlobeStar Therapeutics saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 75,200 shares, a decline of 52.6% from the March 31st total of 158,500 shares. Based on an average daily volume of 20,576,600 shares, the days-to-cover ratio is currently 0.0 days.
View GlobeStar Therapeutics' Short Interest
.

How do I buy shares of GlobeStar Therapeutics?

Shares of GSTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:GSTC) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners